Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Oren Hershkovitz
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Beta
- 1.41
- Country
- IL
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.77
Financials
Net Income
$1.89BEBITDA
$-4.17MFree Cash Flow
$-5.47MEPS (diluted)
$97.80Shares Outstanding (diluted)
19.33M+70666.4%Operating Expenses
$4.23MCash & Debt
$5.52MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $1.24B | $405.60 |
| 2024 | $0.00 | $-15.01M | $-10.95 |
| 2023 | $0.00 | $-29.07M | $-23.40 |
| 2022 | $0.00 | $-31.06M | $-34.65 |
| 2021 | $0.00 | $-14.47M | $-8.10 |
| 2020 | $2.28M | $-11.82M | $-15.75 |
| 2019 | $0.00 | $-9.38M | $-17.55 |
| 2018 | $0.00 | $-4.24M | $-159.45 |
| 2017 | $0.00 | $-5.95M | $-215.25 |
| 2016 | $0.00 | $-16.02M | $-604.35 |
| 2015 | $0.00 | $-15.37M | $-647.85 |
| 2014 | $0.00 | $-7.02M | $-343.65 |
| 2013 | $0.00 | $-1.15M | $-63.15 |
| 2012 | $0.00 | $-229.0K | $-0.13 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $595.91
- Implied price
- $10,726
- Return from $0.20
- 783.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5,333 — today's price is already 100.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 639.3% | 673.0% | 701.7% | 726.8% | 749.2% |
| 3.0% | 677.0% | 712.5% | 742.6% | 769.0% | 792.6% |
| 8.0% | 714.7% | 751.9% | 783.6% | 811.2% | 835.9% |
| 13.0% | 752.5% | 791.4% | 824.5% | 853.4% | 879.2% |
| 18.0% | 790.2% | 830.8% | 865.4% | 895.6% | 922.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
95+18.75%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5h ago·Neutral
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026 Nes-Ziona, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a 1-for-16 reverse split (the “Reverse Split”) of its ordinary shares, which will become effective on October 27, 2026, on which date the Company's ordinary shares will trade on The Nasdaq Capital Market on a split-adjusted…
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
…hase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis Nes-Ziona, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced a cost reduction plan, effective immediately, designed to substantially reduce the Company's cash burn and focus its resources on the execution of its Phase 2b clinical trial of Allocetra™ for the treatment of pa…
View source ↗ - Newszacks.com·51d ago·Negative
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Enlivex Ltd. (ENLV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
View source ↗
Earnings
Fri, Nov 13(in 3 weeks)
Consensus estimate $-0.28 per share
Typical surprise +6.2% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Sep 25$-0.31 vs $-0.31beat
- Mon, Mar 30$-3.45 vs $-0.45miss
- Wed, Mar 25$410.25 vs $-1.29beat
- Fri, Nov 14$-1.35 vs $-1.80beat
- Fri, Aug 29$-1.20 vs $-2.40beat
- Fri, May 30$-2.25 vs $-2.40beat
Estimates and results for ENLV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ENLV officers and directors.
No open-market trades in the recent filings. All 29 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
29 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ENLV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.